Omega Therapeutics Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress
As of September 30, 2023, the Company had cash, cash equivalents and marketable securities totaling $89.3 million.
- As of September 30, 2023, the Company had cash, cash equivalents and marketable securities totaling $89.3 million.
- Research and development (R&D) expenses for the third quarter of 2023 were $16.5 million, compared to $20.7 million for the third quarter of 2022.
- General and administrative (G&A) expenses for the third quarter of 2023 were $7.9 million, compared to $5.2 million for the third quarter of 2022.
- Net loss for the third quarter of 2023 was $22.2 million, compared to $25.8 million for the third quarter of 2022, driven predominantly by a decrease in R&D expenses.